retrovir 300 milligram tablets
viiv healthcare uk ltd - zidovudine - tablets - 300 milligram
retrovir capsule 250 mg
glaxosmithkline pte ltd - zidovudine - capsule - 250 mg
retrovir capsule 100 mg
glaxosmithkline pte ltd - zidovudine - capsule - 100 mg
edurant
j-c health care ltd - rilpivirine as hydrochloride - tablets - rilpivirine as hydrochloride 25 mg - rilpivirine - rilpivirine - edurant™, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-naïve adult patients with hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy.
edurant rilpivirine 25 mg (as hydrochloride) film-coated tablet bottle
janssen-cilag pty ltd - rilpivirine hydrochloride, quantity: 27.5 mg (equivalent: rilpivirine, qty 25 mg) - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; macrogol 3000; croscarmellose sodium; silicon dioxide; magnesium stearate; povidone; polysorbate 20; titanium dioxide; triacetin; microcrystalline cellulose - edurant, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-naive adult patients with viral load less than or equal to 100,000 copies/ml at baseline. this indication is based on week 48 safety and efficacy analyses from 2 randomised double-blind, controlled phase iii trials in treatment-naive adult patients and on week 96 safety and efficacy analyses from the phase iib trial tmc278-c204 in treatment-naive adult patients (see clinical trials section).
rifadin
pharmacy retailing (nz) ltd t/a healthcare logistics - rifampicin 20 mg/ml (5% overage is added.) - oral suspension - 100 mg/5ml - active: rifampicin 20 mg/ml (5% overage is added.) excipient: agar diolamine methyl hydroxybenzoate polysorbate 80 potassium sorbate propyl hydroxybenzoate purified water raspberry saccharin sodium metabisulfite sucrose - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.
atripla
gilead sciences israel ltd - efavirenz; emtricitabine; tenofovir disoproxil as - film coated tablets - tenofovir disoproxil as 245 mg; emtricitabine 200 mg; efavirenz 600 mg - tenofovir disoproxil - tenofovir disoproxil - atripla is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults.
laif 600
bayer israel ltd - hypericum perforatum - film coated tablets - hypericum perforatum 612 mg - symptoms of mild to moderate depression. treatment is recommended for up to 24 weeks.
viracept
roche registration ltd. - nelfinavir - hiv infections - antivirals for systemic use - viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (hiv-1)-infected adults, adolescents and children of three years of age and older.in protease-inhibitor (pi)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.
viraferon
schering-plough europe - interferon alfa-2b - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b: treatment of adult patients with chronic hepatitis b associated with evidence of hepatitis b viral replication (presence of hbv-dna and hbeag), elevated alanine aminotransferase (alt) and histologically proven active liver inflammation and/or fibrosis.chronic hepatitis c:adult patients:introna is indicated for the treatment of adult patients with chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv (see section 4.4).the best way to use introna in this indication is in combination with ribavirin.chidren and adolescents:introna is intended for use, in a combination regimen with ribavirin, for the treatment of children and adolescents 3 years of age and older, who have chronic hepatitis c, not previously treated, without liver decompensation, and who are positive for serum hcv-rna. the decision to treat should be made on a case by case basis, taking into account any evidence of disease progression such as hepatic inflammation and fibrosis, as well as prognostic factors for response, hcv genotype and viral load. the expected benefit of treatment should be weighed against the safety findings observed for paediatric subjects in the clinical trials (see sections 4.4, 4.8 and 5.1).